FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allograft Rejection
Addenbrooke's Hospital, Department of Surgery reports research in allograft rejection
March 15th, 2007
Fresh data on allograft rejection are presented in the report "Abrogation of antibody-mediated allograft rejection by regulatory CD4 T cells with indirect allospecificity. Alloantibody is an important effector mechanism for allograft rejection. In this study, we tested the hypothesis that regulatory T cells with indirect allospecificity can prevent humoral rejection by using a rat transplant model in which acute rejection of MHC class I-disparate PVG.R8 heart grafts by PVG.RT1(u) recipients is mediated by alloantibody and is dependent upon help from CD4 T cells that can recognize the disparate MHC alloantigen only via the indirect pathway," scientists in Cambridge, the United Kingdom...
Source: FDA Law Weekly (2007-03-15)
|
